Systemic and metabolic effects of PDE5-inhibitor drugs

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 1

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Mar 15, 2010; 1(1): 3-7
Published online Mar 15, 2010. doi: 10.4239/wjd.v1.i1.3

Table 3 Causes and main interventions in endothelial dysfunction

Factors associated with endothelial dysfunction	Interventions to correct endothelial dysfunction
Aging	L-arginine
Male sex	Estrogens
Cigarette smoking	Smoking cessation
History of CHD	Antioxidants
Low HDL- and high LDL-COL	Statins
Hypertension	ACE-i
Hyperomocysteinemia	Homocysteine lowering (folates)
Diabetes/obesity	Exercise
Erectile dysfunction	PDE5-i

Citation: Aversa A. Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes 2010; 1(1): 3-7
URL: https://www.wjgnet.com/1948-9358/full/v1/i1/3.htm
DOI: https://dx.doi.org/10.4239/wjd.v1.i1.3

Aversa A. Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes 2010; 1(1): 3-7 [PMID: 21537421 DOI: 10.4239/wjd.v1.i1.3]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.